Zelira’s Promising Entry in Competing with Big Pharma

Zelira’s Therapeutics, Australian player of cannabinoid therapeutics has recently procured Institutional Review Board (IRB) approval focused on pain observational trial which is planned to be conducted in the United States. Zelira’s has planned to conduct tests associated with the company’s patent-protected product going up against a large pharmaceuticals giant’s multi-billion-dollar revenue drug.

Approval secured from the International Review Board suggests that Zelira’s has navigated the mandatory obligatory approval trajectory for the upcoming trial, with the first trial results expected by the year 2022 mid. The primary aim of the trial will be to evaluate the effectiveness and accuracy of Zelira’s offering in treating neuropathic pain as opposed to the major, well-established pharmaceutical drug. Zelira’s Therapeutics is set to go head-to-head against the leading pharmaceutical player.

The company’s Chairman Osagie Imasogie commented that the approval is an optimistic push for Zelira’s enabling the execution of this innovative trial which is intended to offer safe, and effective alternatives for physicians as well as patients as a part of the neuropathic treatment.

With the acquisition of IRB approval, Zelira’s will successfully conduct its trial of the patent-protected product throughout the observational study to be led in the United States, which is scheduled to run for 12 weeks.Even though the specifications of the pharma giant are not published yet, big pharma is generally defined as a suite of multinational, well-established, and highly successful pharmaceutical operations with a significant economic, political as well as social influence.